Other languages Achieve Life Sciences, Inc.

Equities

ACHV

US0044685008

Real-time Estimate Cboe BZX Other stock markets 08:36:10 29/04/2024 pm IST			5-day change	1st Jan Change
4.61 ^USD	0.00%		+4.76%	+12.14%

17/04	JonesTrading Starts Achieve Life Sciences With Buy Rating, $20 Price Target	MT
28/03	Transcript : Achieve Life Sciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Achieve Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Achieve Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/03
Achieve Life Sciences, Inc. Announces Data from Cytisinicline ORCA Program to Be Presented at the 2024 Society for Research on Nicotine and Tobacco Annual Meeting	20/03
Sector Update: Health Care Stocks Decline Late Afternoon	01/03
Sector Update: Health Care	01/03
Achieve Life Sciences Agrees on Safety Exposure Data for Smoking Cessation Medication as Part of NDA	01/03
Top Midday Decliners	13/12
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	12/12
Investors Await Inflation Data, Look to Last Fed Meeting of Year as US Futures Rise Slightly in Tuesday's Premarket	12/12
Top Premarket Decliners	12/12
Achieve Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Achieve Life Sciences, Inc. Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting	11/23/11
Achieve Life Sciences, Inc. Announces Positive Topline Results from A Second Phase 3 ORCA-3 Trial	15/23/15
Achieve Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15
Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association	11/23/11
Achieve Life Sciences Inc Provides Information to Shareholders	10/23/10
Achieve Life Sciences Reports Positive Topline Data From Trial of Cytisinicline; Shares Rise Pre-Bell	23/23/23
Achieve Life Sciences, Inc. Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial	23/23/23
Achieve Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10
Achieve Life Sciences Reports 'Positive' Topline Results From Phase 2 Trial of Cytisinicline for Vaping Cessation	20/23/20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Achieve Life Sciences, Inc.

Equities

ACHV

US0044685008

Other languages

Filters